ZA200402319B - Proaerolysin containing protease activation sequences and methods of use for treatment of prostate cancer. - Google Patents

Proaerolysin containing protease activation sequences and methods of use for treatment of prostate cancer.

Info

Publication number
ZA200402319B
ZA200402319B ZA200402319A ZA200402319A ZA200402319B ZA 200402319 B ZA200402319 B ZA 200402319B ZA 200402319 A ZA200402319 A ZA 200402319A ZA 200402319 A ZA200402319 A ZA 200402319A ZA 200402319 B ZA200402319 B ZA 200402319B
Authority
ZA
South Africa
Prior art keywords
proaerolysin
treatment
methods
prostate cancer
containing protease
Prior art date
Application number
ZA200402319A
Other languages
English (en)
Inventor
Samuel R Denmeade
James Thomas Buckley
John T Isaacs
Original Assignee
Univ Victoria Innovat Dev
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Victoria Innovat Dev filed Critical Univ Victoria Innovat Dev
Publication of ZA200402319B publication Critical patent/ZA200402319B/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001193—Prostate associated antigens e.g. Prostate stem cell antigen [PSCA]; Prostate carcinoma tumor antigen [PCTA]; PAP or PSGR
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001193—Prostate associated antigens e.g. Prostate stem cell antigen [PSCA]; Prostate carcinoma tumor antigen [PCTA]; PAP or PSGR
    • A61K39/001194—Prostate specific antigen [PSA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001193—Prostate associated antigens e.g. Prostate stem cell antigen [PSCA]; Prostate carcinoma tumor antigen [PCTA]; PAP or PSGR
    • A61K39/001195—Prostate specific membrane antigen [PSMA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/32—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Bacillus (G)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/32—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Bacillus (G)
    • C07K14/325—Bacillus thuringiensis crystal peptides, i.e. delta-endotoxins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/33—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Clostridium (G)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/52—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from bacteria or Archaea
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biophysics (AREA)
  • Microbiology (AREA)
  • Cell Biology (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Immunology (AREA)
  • Oncology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biotechnology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Engineering & Computer Science (AREA)
  • Urology & Nephrology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
ZA200402319A 2001-08-24 2004-03-23 Proaerolysin containing protease activation sequences and methods of use for treatment of prostate cancer. ZA200402319B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US31461301P 2001-08-24 2001-08-24

Publications (1)

Publication Number Publication Date
ZA200402319B true ZA200402319B (en) 2005-08-30

Family

ID=23220660

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA200402319A ZA200402319B (en) 2001-08-24 2004-03-23 Proaerolysin containing protease activation sequences and methods of use for treatment of prostate cancer.

Country Status (11)

Country Link
US (3) US7282476B2 (https=)
EP (2) EP2518142B1 (https=)
JP (1) JP4319908B2 (https=)
CN (1) CN100488981C (https=)
AU (1) AU2002331720B2 (https=)
CA (1) CA2457903C (https=)
DK (1) DK1567641T3 (https=)
ES (2) ES2542888T3 (https=)
PT (1) PT1567641E (https=)
WO (1) WO2003018611A2 (https=)
ZA (1) ZA200402319B (https=)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8809504B2 (en) * 2002-09-03 2014-08-19 Vit Lauermann Inhibitor which is deactivatable by a reagent produced by a target cell
WO2004078097A2 (en) * 2003-03-03 2004-09-16 University Of Victoria Innovation And Development Corporation Modified aerolysin linked to a lung cancer binding agent and methods of use for treating lung cancer
EP1694845B8 (en) 2003-11-28 2017-12-20 National Research Council of Canada Anticarcinoma antibodies and uses thereof
ATE502954T1 (de) * 2005-06-14 2011-04-15 Protox Therapeutics Inc Verfahren zur behandlung oder prävention gutartiger prostatahyperplasie unter verwendung modifizierter porenbildender proteine
CN100443503C (zh) * 2005-07-18 2008-12-17 四川大学华西医院 人源化ctla-4单链抗体与人穿孔素通道形成肽p34的重组免疫毒素
CA2630559A1 (en) * 2005-11-21 2007-05-24 Protox Therapeutics Incorporated Modified pore-forming protein toxins and use thereof
US8993295B2 (en) 2006-07-20 2015-03-31 The General Hospital Corporation Methods, compositions, and kits for the selective activation of protoxins through combinatorial targeting
PL2187965T3 (pl) 2007-08-17 2020-05-18 Purdue Research Foundation Koniugaty wiążący psma ligand-łącznik i sposoby ich zastosowania
JP2012512183A (ja) 2008-12-15 2012-05-31 プロトックス セラピューティクス インコーポレイテッド 改変された孔形成性タンパク質プロアエロリシンを用いた前立腺炎の処置のための方法
CA2780153A1 (en) 2009-11-09 2011-05-12 Alexion Pharmaceuticals, Inc. Reagents and methods for detecting pnh type ii white blood cells and their identification as risk factors for thrombotic disorders
US9951324B2 (en) 2010-02-25 2018-04-24 Purdue Research Foundation PSMA binding ligand-linker conjugates and methods for using
AU2011316786A1 (en) * 2010-10-22 2013-05-02 Protox Therapeutics Corp. Use of human serum albumin to decrease antigenicity of therapeutic proteins
EA201590783A1 (ru) 2012-11-15 2015-11-30 Эндосайт, Инк. Конъюгаты для доставки лекарственных средств и способы лечения заболеваний, вызванных клетками, экспрессирующими psma
US9789209B2 (en) 2013-03-14 2017-10-17 The Regents Of The University Of California, Berke Activatable membrane-interacting peptides and methods of use
EP3456700A1 (en) 2013-10-18 2019-03-20 Deutsches Krebsforschungszentrum Labeled inhibitors of prostate specific membrane antigen (psma), their use as imaging agents and pharmaceutical agents for the treatment of prostate cancer
US10464970B2 (en) 2013-10-23 2019-11-05 The United States Of America As Represented By The Secretary, Department Of Health And Human Services Compounds that bind to human immunodeficiency virus rev response element
EP3533473A3 (en) 2013-11-14 2019-12-18 Endocyte, Inc. Compounds for positron emission tomography
US10188759B2 (en) 2015-01-07 2019-01-29 Endocyte, Inc. Conjugates for imaging
US10596226B2 (en) * 2015-01-16 2020-03-24 The Johns Hopkins University Albumin-proaerolysin prodrugs
US10676723B2 (en) 2015-05-11 2020-06-09 David Gordon Bermudes Chimeric protein toxins for expression by therapeutic bacteria
CN108601817A (zh) * 2016-01-27 2018-09-28 索飞瑞斯生物公司 靶向前列腺内给予prx302用于治疗前列腺癌的方法
CN109790206A (zh) * 2016-09-22 2019-05-21 分子组合公司 重组结合蛋白及其用途
US11180535B1 (en) 2016-12-07 2021-11-23 David Gordon Bermudes Saccharide binding, tumor penetration, and cytotoxic antitumor chimeric peptides from therapeutic bacteria
EP3694558B1 (en) 2017-10-10 2024-04-10 Medicenna Therapeutics Inc. Il-4-fusion formulations for treatment of central nervous system (cns) tumors
CN112368024A (zh) 2018-04-17 2021-02-12 恩多塞特公司 治疗癌症的方法
CN114096264B (zh) 2019-05-20 2025-03-14 因多塞特股份有限公司 制备psma缀合物的方法
EP4100038A4 (en) 2020-02-03 2024-02-28 Premas Biotech Private Limited RECOMBINANT EXPRESSION PLATFORM, CONSTRUCTS AND METHODS FOR EXPRESSING HARD-TO-EXPRESS PROTEINS (DTE-PS)
US11845779B2 (en) * 2020-10-28 2023-12-19 Ecole Polytechnique Federale De Lausanne (Epfl) Mutant aerolysin and uses thereof

Family Cites Families (57)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US4797368A (en) 1985-03-15 1989-01-10 The United States Of America As Represented By The Department Of Health And Human Services Adeno-associated virus as eukaryotic expression vector
US5264550A (en) 1985-04-15 1993-11-23 Scios Nova Inc. Human anti-inflammatory phospholipase inhibitor protein
US4980286A (en) 1985-07-05 1990-12-25 Whitehead Institute For Biomedical Research In vivo introduction and expression of foreign genetic material in epithelial cells
US5858358A (en) 1992-04-07 1999-01-12 The United States Of America As Represented By The Secretary Of The Navy Methods for selectively stimulating proliferation of T cells
US5529774A (en) 1991-08-13 1996-06-25 The Regents Of The University Of California In vivo transfer of the HSV-TK gene implanted retroviral producer cells
FR2686899B1 (fr) 1992-01-31 1995-09-01 Rhone Poulenc Rorer Sa Nouveaux polypeptides biologiquement actifs, leur preparation et compositions pharmaceutiques les contenant.
US6057133A (en) 1992-11-24 2000-05-02 G. D. Searle Multivariant human IL-3 fusion proteins and their recombinant production
US5677274A (en) 1993-02-12 1997-10-14 The Government Of The United States As Represented By The Secretary Of The Department Of Health And Human Services Anthrax toxin fusion proteins and related methods
US5777078A (en) * 1993-04-28 1998-07-07 Worcester Foundation For Experimental Biology Triggered pore-forming agents
WO1994025616A1 (en) 1993-04-28 1994-11-10 Worcester Foundation For Experimental Biology Cell-targeted lytic pore-forming agents
ATE293686T1 (de) 1993-06-04 2005-05-15 Us Navy Verfahren zur selektiven stimulierung der t- zellproliferation.
US5691188A (en) 1994-02-14 1997-11-25 American Cyanamid Company Transformed yeast cells expressing heterologous G-protein coupled receptor
WO1995026204A1 (en) 1994-03-25 1995-10-05 Isis Pharmaceuticals, Inc. Immune stimulation by phosphorothioate oligonucleotide analogs
CA2188675A1 (en) 1994-04-11 1995-10-19 Savio L. C. Woo Compositions and methods for gene therapy to treat disease
US5866679A (en) 1994-06-28 1999-02-02 Merck & Co., Inc. Peptides
US5599686A (en) 1994-06-28 1997-02-04 Merck & Co., Inc. Peptides
US6143864A (en) * 1994-06-28 2000-11-07 Merck & Co., Inc. Peptides
US6207646B1 (en) 1994-07-15 2001-03-27 University Of Iowa Research Foundation Immunostimulatory nucleic acid molecules
EP1167379A3 (en) 1994-07-15 2004-09-08 University Of Iowa Research Foundation Immunomodulatory oligonucleotides
US6190657B1 (en) 1995-06-07 2001-02-20 Yale University Vectors for the diagnosis and treatment of solid tumors including melanoma
US6066319A (en) 1996-04-30 2000-05-23 President And Fellows Of Harvard College Drug delivery using terminal complement components
US6072041A (en) 1996-06-03 2000-06-06 Case Western Reserve University Fusion proteins for protein delivery
US5856462A (en) 1996-09-10 1999-01-05 Hybridon Incorporated Oligonucleotides having modified CpG dinucleosides
US5998362A (en) 1996-09-12 1999-12-07 Merck & Co., Inc. Conjugates useful in the treatment of prostate cancer
US6368598B1 (en) 1996-09-16 2002-04-09 Jcrt Radiation Oncology Support Services, Inc. Drug complex for treatment of metastatic prostate cancer
US5798218A (en) 1996-09-24 1998-08-25 University Of British Columbia Innovation And Development Corporation Compositions and methods for the specific detection of thy-1 antigen
US5948750A (en) 1996-10-30 1999-09-07 Merck & Co., Inc. Conjugates useful in the treatment of prostate cancer
JP2001504334A (ja) * 1996-11-06 2001-04-03 アメリカ合衆国 プロテアーゼ活性化可能なＰｓｅｕｄｏｍｏｎａｓ体外毒素Ａ様プロタンパク質
WO1998037919A1 (en) 1997-02-28 1998-09-03 University Of Iowa Research Foundation USE OF NUCLEIC ACIDS CONTAINING UNMETHYLATED CpG DINUCLEOTIDE IN THE TREATMENT OF LPS-ASSOCIATED DISORDERS
DK1005368T3 (da) 1997-03-10 2010-01-04 Ottawa Hospital Res Inst Anvendelse af nukleinsyrer, der indeholder ikke-metyleret CpG dinukleotid i kombination med alun som hjælpestoffer
EP1005376B1 (en) 1997-03-14 2010-11-03 The Children's Hospital of Philadelphia Compositions for use in gene therapy for treatment of hemophilia
US6504014B1 (en) * 1997-05-19 2003-01-07 The John Hopkins University Tissue specific prodrug
US6545131B1 (en) * 1997-05-19 2003-04-08 The Johns Hopkins University Tissue specific prodrug
US6265540B1 (en) * 1997-05-19 2001-07-24 The Johns Hopkins University School Of Medicine Tissue specific prodrug
EP1003531B1 (en) 1997-05-20 2007-08-22 Ottawa Health Research Institute Processes for preparing nucleic acid constructs
AU740597B2 (en) 1997-07-10 2001-11-08 Merck & Co., Inc. Conjugates useful in the treatment of prostate cancer
CA2299471C (en) * 1997-08-15 2007-12-18 Cephalon Inc. Combination of tyrosine kinase inhibitor and chemical castration to treat prostate cancer
US6391305B1 (en) 1997-09-10 2002-05-21 Merck & Co., Inc. Conjugates useful in the treatment of prostate cancer
GB9721901D0 (en) 1997-10-16 1997-12-17 Univ Manchester Particles
CA2318127A1 (en) * 1998-01-20 1999-07-22 University Of Victoria Innovation And Development Corporation Detection of gpi anchored proteins
US6180356B1 (en) * 1998-03-06 2001-01-30 The Research Foundation Of State University Of Ny Membrane pore inhibiting agents for treating infection
US6221349B1 (en) 1998-10-20 2001-04-24 Avigen, Inc. Adeno-associated vectors for expression of factor VIII by target cells
WO2000061613A2 (en) * 1999-04-09 2000-10-19 The Johns Hopkins University Channel forming toxins as antiviral agents
WO2000067796A1 (en) 1999-05-07 2000-11-16 Genentech, Inc. Treatment of autoimmune diseases with antagonists which bind to b cell surface markers
EP1052287A3 (en) 1999-05-10 2003-07-09 Transgene S.A. Complex for transferring an anionic substance of interest into a cell
EP1052288A1 (en) 1999-05-10 2000-11-15 Transgene S.A. Complex for transferring an anionic substance of interest into a cell
WO2001009165A2 (en) 1999-07-29 2001-02-08 The Johns Hopkins University ACTIVATION OF PEPTIDE PRODRUGS BY hK2
US7053042B1 (en) * 1999-07-29 2006-05-30 Samuel Denmeade Activation of peptide prodrugs by hK2
JP2003511082A (ja) 1999-10-12 2003-03-25 ザ・ユニヴァーシティ・オヴ・ノース・キャロライナ・アト・チャペル・ヒル 第ｖｉｉｉ因子をコードするアデノ随伴ウィルスベクターとその使用法
PT1225898E (pt) * 1999-11-01 2003-10-31 Alcon Inc Composicoes farmaceuticas contendo um farmaco antibiotico de fluoroquinolona e goma xantana
AU2001259837A1 (en) 2000-05-09 2001-11-20 Greenville Hospital System Therapeutic pore-forming peptides
US20020041880A1 (en) 2000-07-05 2002-04-11 Defeo-Jones Deborah Method of treating cancer
FI116467B (fi) 2000-09-29 2005-11-30 Licentia Oy Uudet peptidiligandit
WO2002038799A2 (en) 2000-11-07 2002-05-16 University Of Victoria Innovation And Development Corporation Detection of proteases and screening for protease inhibitors
WO2002043773A2 (en) 2000-12-01 2002-06-06 The Johns Hopkins University Tissue specific prodrugs
US7456146B2 (en) 2001-05-09 2008-11-25 Ghc Research Development Corporation Lytic peptide prodrugs

Also Published As

Publication number Publication date
US7838266B2 (en) 2010-11-23
WO2003018611A2 (en) 2003-03-06
CA2457903A1 (en) 2003-03-06
ES2542888T3 (es) 2015-08-12
JP2005520490A (ja) 2005-07-14
ES2388170T3 (es) 2012-10-09
DK1567641T3 (da) 2012-08-27
US7745395B2 (en) 2010-06-29
EP2518142A1 (en) 2012-10-31
EP1567641A4 (en) 2005-12-28
PT1567641E (pt) 2012-08-21
CA2457903C (en) 2018-04-17
US20080089869A1 (en) 2008-04-17
EP1567641A2 (en) 2005-08-31
AU2002331720B2 (en) 2007-10-11
EP2518142B1 (en) 2015-07-15
WO2003018611A3 (en) 2005-06-30
JP4319908B2 (ja) 2009-08-26
CN1636017A (zh) 2005-07-06
US20040235095A1 (en) 2004-11-25
EP1567641B1 (en) 2012-05-23
CN100488981C (zh) 2009-05-20
US7282476B2 (en) 2007-10-16
US20100234300A1 (en) 2010-09-16
HK1178563A1 (en) 2013-09-13

Similar Documents

Publication Publication Date Title
ZA200402319B (en) Proaerolysin containing protease activation sequences and methods of use for treatment of prostate cancer.
IL251270A0 (en) Cancer treatment
GB2393202B (en) Methods of well treatment
HUP0203968A3 (en) Compositions and methods for the therapy and diagnosis of prostate cancer
IL158273A0 (en) Use of bisphosphonates in the treatment of bone metastasis associated with prostate cancer
AU6147401A (en) Compositions and methods for the treatment of cancer
AU2001276039A1 (en) Methods and apparatus for brachytherapy treatment of prostate disease
AU2002340168A1 (en) Treatment of prostate cancer by inhibitors of ncam2
AU2002252456A1 (en) Combination treatment of pancreatic cancer
AUPQ923100A0 (en) Treatment of prostate cancer
HUP0500424A2 (en) Combination therapy for the treatment of cancer
MXPA03008582A (es) Agentes y metodos para tratamiento de cancer.
PL375527A1 (en) Arylcarbonylpiperazines and heteroarylcarbonylpiperazines and the use thereof for treating benign and malignant tumour diseases
IL158206A0 (en) Compositions and methods for the prevention and treatment of human prostate cancer
AU7129700A (en) Ovarian tumor sequences and methods of use therefor
IL145397A0 (en) Compositions and methods for treatment of cancer
MXPA03007036A (es) Metodo de terapia para cancer.
PL373346A1 (en) Water-soluble porphyrin platinum compounds with high tumor selectivity and their use for the treatment of benign and malignant tumor diseases
GB2389532C (en) The method of treating cancer
PL368035A1 (en) Compositions and methods for the treatment of cancer
AU2001241779A1 (en) Method of treatment of prostate cancer
GB0124124D0 (en) Methods of treatment
EP1250145A4 (en) PEPTIDES DERIVED FROM ONCOGENE C-SKI FOR THE PREVENTION, TREATMENT AND DIAGNOSIS OF CANCER
AU2004281077A1 (en) Methods and agents for the treatment of cancer
AU2001297571A1 (en) Detection and treatment of prostate cancer